| A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations (NCT05801029) | AstraZeneca | 2023-07-18 |
| Brazilian Reality in the Diagnosis and Treatment of Diffuse Large B Cell Lymphoma - BRA-DLBCL (NCT05958134) | AstraZeneca | 2023-07-15 |
| A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation (NCT05877599) | AstraZeneca | 2023-07-12 |
| PICAROS - Acalabrutinib RWE on 1L CLL in Spain (NCT05999877) | AstraZeneca | 2023-07-11 |
| Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors (NCT06005493) | AstraZeneca | 2023-07-11 |
| A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer (NCT05775549) | AstraZeneca | 2023-07-10 |
| Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER (NCT05945108) | AstraZeneca | 2023-07-10 |
| An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer (NCT05592483) | AstraZeneca | 2023-07-07 |
| A Non-interventional Prospective Study of Early HER2-negative High-risk Breast Cancer and BRCA1/2 Mutations Prevalence in RussiA (NCT05939128) | AstraZeneca | 2023-06-30 |
| Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) (NCT05883644) | AstraZeneca | 2023-06-27 |
| To Determine the Accuracy of SCreening for Occult REnal Disease (SCORED) Questionnaire for CKD Risk Among Asian Patients (NCT05866276) | AstraZeneca | 2023-06-22 |
| A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation (NCT05918042) | AstraZeneca | 2023-06-21 |
| Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study (NCT05665374) | AstraZeneca | 2023-06-19 |
| A Phase I Study to Investigate the Effect of Hepatic Impairment on the PK, Safety, and Tolerability of AZD2693 (NCT05919069) | AstraZeneca | 2023-06-16 |
| Study to Assess Effect of Next-Generation Propellant MDI on Mucociliary Clearance Vs. HFA Propellant MDI in Healthy Participants (NCT05755932) | AstraZeneca | 2023-06-14 |
| Imfinzi BTC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI (NCT05835778) | AstraZeneca | 2023-06-06 |
| Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors (NCT05797168) | AstraZeneca | 2023-06-05 |
| A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects (NCT05888207) | AstraZeneca | 2023-06-02 |
| Outcomes in Real-life After Initation of Treatment With Trixeo (Budesonide / Glycopyrronium / Formoterol) (NCT05862545) | AstraZeneca | 2023-06-01 |
| HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in Russia (NCT05905939) | AstraZeneca | 2023-05-31 |
| HER2-low Unresectable and/or Metastatic Breast Cancer in Russia (NCT05913440) | AstraZeneca | 2023-05-30 |
| HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in Russia (NCT05892926) | AstraZeneca | 2023-05-30 |
| A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants. (NCT05644600) | AstraZeneca | 2023-05-26 |
| Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study (NCT05872958) | AstraZeneca | 2023-05-19 |
| Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study (NCT05667064) | AstraZeneca | 2023-05-09 |
| Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T) (NCT05629234) | AstraZeneca | 2023-05-08 |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants (NCT05848440) | AstraZeneca | 2023-05-02 |
| Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma (NCT05850494) | AstraZeneca | 2023-05-02 |
| A PET Study to Determine Biodistribution and Binding Characteristics of [11C]AZ14132516 in Healthy Participants (NCT05818514) | AstraZeneca | 2023-04-27 |
| A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2 (NCT05737940) | AstraZeneca | 2023-04-24 |
| Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (NCT05775159) | AstraZeneca | 2023-04-24 |
| Validating Artificial Intelligence Effectiveness Defined Lung Nodule Malignancy Score in Patients With Pulmonary Nodule. (NCT05817110) | AstraZeneca | 2023-04-20 |
| An ADME Study of [14C]AZD0780 in Healthy Male Subjects (NCT05817461) | AstraZeneca | 2023-04-19 |
| A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Elarekibep in Healthy Japanese Subjects (NCT05794672) | AstraZeneca | 2023-04-11 |
| A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (NCT05692180) | AstraZeneca | 2023-04-05 |
| TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS) (NCT05729711) | AstraZeneca | 2023-04-04 |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (NCT05774951) | AstraZeneca | 2023-03-31 |
| CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia (NCT05887011) | AstraZeneca | 2023-03-31 |
| A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in Participants With Suspected NASH. (NCT05864391) | AstraZeneca | 2023-03-31 |
| Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia (NCT05891847) | AstraZeneca | 2023-03-21 |
| Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment (NCT05751759) | AstraZeneca | 2023-03-20 |
| A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis (NCT05809934) | AstraZeneca | 2023-03-15 |
| A Study to Assess the Effect of AZD0780 on the Pharmacokinetics of Rosuvastatin. (NCT05787002) | AstraZeneca | 2023-03-09 |
| eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services (NCT05712096) | AstraZeneca | 2023-03-09 |
| LYNPARZA Breast Cancer in the Adjuvant Setting Japan Post-Marketing Surveillance (PMS) (NCT05677308) | AstraZeneca | 2023-03-07 |
| Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO). (NCT05742802) | AstraZeneca | 2023-03-06 |
| A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (NCT05526755) | AstraZeneca | 2023-03-06 |
| A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma (LITHOS) (NCT05755906) | AstraZeneca | 2023-02-27 |
| A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice (NCT05637112) | AstraZeneca | 2023-02-27 |
| Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects (NCT05790304) | AstraZeneca | 2023-02-20 |
| Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm (NCT05546866) | AstraZeneca | 2023-02-09 |
| Patient-Reported Outcomes of Benralizumab in Real-World Use in Severe Eosinophilic Asthma Patients in Taiwan (BEAT) (NCT05734339) | AstraZeneca | 2023-01-19 |
| Uptake of the Childhood Live Attenuated Influenza Vaccine (LAIV) and Influenza-related Healthcare Resource Use in England During the 2012 to 2022 Flu Seasons; a Retrospective, Observational Study in the CPRD and HES Databases (NCT06077045) | AstraZeneca | 2023-01-18 |
| Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (NCT05702229) | AstraZeneca | 2023-01-16 |
| eVusheld Assessment reaL wORld Effectiveness at UPMC (NCT05667116) | AstraZeneca | 2023-01-09 |
| Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS) (NCT05687877) | AstraZeneca | 2023-01-06 |
| eVusheld Assessment reaL wORld Effectiveness in the VA Health System (NCT05663957) | AstraZeneca | 2023-01-04 |
| A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants (NCT05668936) | AstraZeneca | 2023-01-03 |
| A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region (NCT06039683) | AstraZeneca | 2022-12-31 |
| Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (NCT05687266) | AstraZeneca | 2022-12-29 |
| Real-world Dapagliflozin Experience in Patients With Heart Failure in Greece (NCT05635331) | AstraZeneca | 2022-12-28 |
| Study on Determine the Utilisation and Clinical Outcomes of Evusheld in COVID-19 PrEP in China (NCT05917951) | AstraZeneca | 2022-12-24 |
| First in Human Study of AZD9592 in Solid Tumors (NCT05647122) | AstraZeneca | 2022-12-21 |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186 (NCT05694741) | AstraZeneca | 2022-12-20 |
| Parent Study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOvel Anitbodies (SUPERNOVA Sub-study) (NCT05648110) | AstraZeneca | 2022-12-16 |
| A Study for Observing Severe Asthma in Patients Treated With Tezepelumab (NCT05677139) | AstraZeneca | 2022-12-13 |
| Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (NCT05624450) | AstraZeneca | 2022-12-13 |
| Multiple Dose Study of Safety and Pharmacokinetics of MEDI0618 in Healthy Volunteers (NCT05714254) | AstraZeneca | 2022-12-12 |
| Retention Rate of Acalabrutinib in a Non-interventional Setting (NCT05645172) | AstraZeneca | 2022-12-12 |
| MEDI5752 in Japanese Patients With Advanced Solid Tumors. (NCT05685472) | AstraZeneca | 2022-12-08 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State. (NCT05662033) | AstraZeneca | 2022-12-05 |
| A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) (NCT05629585) | AstraZeneca | 2022-11-28 |
| Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC (NCT05374603) | AstraZeneca | 2022-11-15 |
| An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD. (NCT05492877) | AstraZeneca | 2022-11-14 |
| A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer. (NCT05683977) | AstraZeneca | 2022-11-14 |
| Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis (NCT05583227) | AstraZeneca | 2022-11-10 |
| Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer (NCT05498155) | AstraZeneca | 2022-11-07 |
| Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies (NCT05573724) | AstraZeneca | 2022-11-07 |
| Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study) (NCT05516498) | AstraZeneca | 2022-10-31 |
| A Study in Participants With Non-cirrhotic NASH With Fibrosis (NCT05638737) | AstraZeneca | 2022-10-26 |
| Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom (NCT05557695) | AstraZeneca | 2022-10-17 |
| A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant (NCT05569421) | AstraZeneca | 2022-10-11 |
| BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging (NCT05552508) | AstraZeneca | 2022-10-11 |
| A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole (NCT05551897) | AstraZeneca | 2022-10-04 |
| Exacerbations Among Patients Receiving Breztri (EROS Study) (NCT06514144) | AstraZeneca | 2022-10-01 |
| PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction (NCT05555290) | AstraZeneca | 2022-09-28 |
| A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With a Next-Generation Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (NCT05573464) | AstraZeneca | 2022-09-27 |
| A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy (NCT05450692) | AstraZeneca | 2022-09-15 |
| Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed (NCT05548777) | AstraZeneca | 2022-09-15 |
| National Acalabrutinib Observational Study (NCT05437250) | AstraZeneca | 2022-09-13 |
| A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT05057494) | AstraZeneca | 2022-09-12 |
| Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment (NCT05517226) | AstraZeneca | 2022-09-06 |
| Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) (NCT05489211) | AstraZeneca | 2022-09-06 |
| A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users. (NCT05587998) | AstraZeneca | 2022-08-31 |
| A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers (NCT05512806) | AstraZeneca | 2022-08-24 |
| Assessing the Effect of Multiple Doses of Zibotentan on the Pharmacokinetics of Single Doses of Combined Oral Contraceptives in Healthy Female Participants of Non-childbearing Potential. (NCT05505162) | AstraZeneca | 2022-08-24 |
| Safety of Oral Resin for Treatment of Hyperkalemia in Chinese Patients With Renal Insufficiency (NCT05462119) | AstraZeneca | 2022-08-22 |
| Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease (NCT05560607) | AstraZeneca | 2022-08-12 |
| A Study to Assess the Relative Bioavailability and Safety of Different Formulations of AZD4831 in Fasted State in Healthy Volunteers. (NCT05457270) | AstraZeneca | 2022-08-11 |
| REported Outcomes in COPD With Trixeo in Real worlD (NCT05213611) | AstraZeneca | 2022-08-11 |